All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 134 of 206 pages ‹ First < 132 133 134 135 136 > Last ›
HSL724
Santini , L .
Drug Companies Look to China For Cheap R&D
THE WALL STREET JOURNAL 2004 Nov 22
HSL1173
L-carnitine
Med Lett Drugs Ther 2004 Nov 22;46:(1196):95-6
HSL770
How the drug cartel thrives
Sunday Herald 2004 Nov 21
HSL135
Drug companies blinded by quest for profit
Montreal Gazette 2004 Nov 19
HSL136
Liberal's plan to get discount medicines to poor nations panned
Globe and Mail 2004 Nov 19
HSL5381
United States Senate Committee on Finance Web page
Testimony of David J. Graham, MD, MPH
: United States Senate Committee on Finance Web page 2004 Nov 18
http://finance.senate.gov/hearings/testimony/2004test/111804dgtest.pdf
HSL4447
Mansfield PR.
Safety Query.
Australian Doctor Weekly 2004 Nov 17
HSL17369
Sedgman J
GPs seek right to give drug info to pharmaceutical firms
PM : ABC Radio National 2004 Nov 17
http://www.abc.net.au/pm/content/2004/s1245798.htm
HSL133
Proposal will save health cash: MP
Windsor Star 2004 Nov 15
HSL5285
Langton PE, Hankey GJ, Eikelboom JW.
Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events.
Med J Aust 2004 Nov 15;181:(10):524-5
http://www.mja.com.au/public/issues/181_10_151104/lan10728_fm.html
HSL11539
Anand G.
How Drugs for Rare Diseases Became Lifeline for Companies
The Wall Street Journal 2004 Nov 15A1
http://online.wsj.com/article/SB113202332063297223.html?mod=yahoo_hs&ru=yahoo
HSL19948
Limprecht E
GPs paid peanuts for data
Australian Doctor 2004 Nov 121
http://www.australiandoctor.com.au/news/gps-paid-peanuts-for-data
HSL19949
Burge K
Data sales risk patient trust
Medical Observer 2004 Nov 129
http://www.rheumatologyupdate.com.au/news/data-sales-risk-patient-trust---mo-news
HSL19957
Borland J
Copyright-sharing group delves into science
CNet News.com 2004 Nov 10
http://news.cnet.com/2100-1025_3-5447531.html
HSL1794
Abraham J.
Pharmaceuticals, the state and the global harmonisation process.
Aust Health Rev 2004 Nov 8;28:(2):150-60
http://www.aushealthreview.com.au/publications/articles/issues/ahr_28_2_081104/ahr_28_2_150-160.asp
HSL764
Moran , M .
AMA to Study Safety of SSRIs In Youngsters
Psychiatric News 2004 Nov 5
HSL19955
Limprecht E
'Toe tag' ad stirs more debate
Australian Doctor 2004 Nov 3
http://www.australiandoctor.com.au/news/--8216;toe-tag--8217;-ad-stirs-more-debate
HSL1827
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school.
Acad Med. 2004 Nov;79(11):1041-5. 2004 Nov 01;79:(11):1041-5
http://www.academicmedicine.org/cgi/content/full/79/11/1041
HSL5417
Dybdahl T, Andersen M, Sondergaard J, Kragstrup J, Kristiansen IS.
Does the early adopter of drugs exist ? A population-based study of general practitioners' prescribing of new drugs.
Eur J Clin Pharmacol 2004 Nov 01;60:(9):667-72
http://www.springerlink.com/(qwbstlvsg40bdiuu3sqlkg45)/app/home/contribution.asp?referrer=parent&backto=issue,9,12;journal,24,394;linkingpublicationresults,1:100413,1
HSL17368
Wilde Mathews A, Martinez B
Warning Signs: E-Mails Suggest Merck Knew Vioxx's Dangers at Early Stage As Heart-Risk Evidence Rose, Officials Played Hardball; Internal Message: 'Dodge!'
The Wall Street Journal 2004 Nov 1
http://www.marshall-attorneys.com/Press/2004_11_01_WSJ.htm
HSL285
Allen K, Mansfield P.
Changing attitudes to 'the change'.
Aust Fam Physician 2004 Nov;33:(11):939-40
http://www.racgp.org.au/document.asp?id=15004
HSL354
Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov;13:(11):797-9
http://www3.interscience.wiley.com/cgi-bin/abstract/107632790/ABSTRACT
HSL1153
Wazana A, Granich A, Primeau F, Bhanji NH, Jalbert M.
Using the literature in developing McGill's guidelines for interactions between residents and the pharmaceutical industry.
Acad Med 2004 Nov;79:(11):1033-40
http://www.academicmedicine.org/cgi/content/full/79/11/1033
HSL1458
Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A.
Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals.
Pharmacoepidemiol Drug Saf 2004 Nov;13:(11):789-95
http://www3.interscience.wiley.com/cgi-bin/abstract/109712611/ABSTRACT
HSL1780
Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM.
Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement.
J Health Commun 2004 Nov-Dec;9:(6):491-7
http://www.ncbi.nlm.nih.gov/pubmed/15764448
HSL1791
Ahmed SB, Grace SL, Stelfox HT, Tomlinson G, Cheung AM.
Gender bias in cardiovascular advertisements.
J Eval Clin Pract 2004 Nov;10:(4):531-8
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2753.2003.00483.x
HSL1792
Ahmed SB, Grace SL, Stelfox HT, Tomlinson G, Cheung AM.
Portrayal of female physicians in cardiovascular advertisements.
Can J Cardiol 2004 Nov;20:(13):1351-4
HSL1793
Agrawal S, Saluja I, Kaczorowski J.
A prospective before-and-after trial of an educational intervention about pharmaceutical marketing.
Acad Med 2004 Nov;79:(11):1046-50
http://www.academicmedicine.org/cgi/content/full/79/11/1046
HSL1885
O'Donnell MJ, Molloy DW, Smith SD, Dubois S, Russo RM.
The self-perceived role and educational needs of pharmaceutical representatives: a survey.
Educ Health (Abingdon) 2004 Nov;17:(3):339-45
HSL1886
Huh J, Cude BJ.
Is the information
J Health Commun 2004 Nov-Dec;9:(6):529-40
http://www.ncbi.nlm.nih.gov/pubmed/15764451
HSL4894
Moynihan R.
The intangible magic of celebrity marketing.
PLoS Med 2004 Nov;1:(2):e42
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15578110
HSL20047
Metzl JM, Howell JD
Making History: Lessons from the Great Moments Series of Pharmaceutical Advertisements
Academic Medicine 2004 Nov;79:(11):1027-1032
http://journals.lww.com/academicmedicine/fulltext/2004/11000/making_history__lessons_from_the_great_moments.3.aspx
HSL366
Sweet M.
Doctors and drug companies are locked in 'vicious circle'.
BMJ 2004 Oct 30;329:(7473):998
http://bmj.bmjjournals.com/cgi/content/full/329/7473/998
HSL5472
Mansfield PR.
Reform of incentives would help reduce harm from drug promotion
BMJ 2004 Oct 30;329:
http://bmj.bmjjournals.com/cgi/eletters/329/7473/998
HSL12191
Gabbay J, le May A.
Evidence based guidelines or collectively constructed "mindlines?" Ethnographic study of knowledge management in primary care
BMJ 2004 Oct 30;329:(7473):1013
http://www.bmj.com/cgi/content/full/329/7473/1013
HSL19842
Hungerford C
Insulting ad
Australian Doctor 2004 Oct 2925
HSL15712
Blumenthal D.
Doctors and drug companies.
N Engl J Med. 2004 Oct 28;351:(18):1885-90
http://content.nejm.org/cgi/content/extract/351/18/1885
HSL19512
Studdert DM, Mello MM, Brennan TA
Financial conflicts of interest in physician relationships with pharmaceutical companies--self regulation in the shadow of federal prosecution.
NEJM 2004 Oct 28;351:1891-1900
http://www.nejm.org/doi/full/10.1056/NEJMlim042229
HSL19741
Ed.
The mechanics of marketing ROI
eyeforpharma.com 2004 Oct 28
http://social.eyeforpharma.com/uncategorised/mechanics-marketing-roi
HSL995
Ranald P.
A clear choice: abandon or defend FTA
Australian Financial Review 2004 Oct 22
HSL994
Davidson K.
Can we please get serious?: The US free trade deal may be a disaster for Australia. Not that our politicians seem to care
The Age 2004 Oct 21
HSL1891
Aasland OG, Forde R.
[Physicians and drug industry: attitudes and practice].
Tidsskr Nor Laegeforen 2004 10 21;124:(20):2603-6
http://www.tidsskriftet.no/pls/lts/pa_lt.visSeksjon?vp_SEKS_ID=1083681
HSL3679
Topol EJ.
Failing the public health--rofecoxib, Merck, and the FDA.
N Engl J Med 2004 Oct 21;351:(17):1707-9
http://content.nejm.org/cgi/content/extract/351/17/1707
HSL5422
Fitzgerald GA.
Coxibs and cardiovascular disease.
N Engl J Med 2004 Oct 21;351:(17):1709-11
http://content.nejm.org/cgi/content/extract/351/17/1709
HSL20240
Taylor RS, Drummond MF, Salkeld G, Sullivan SD
Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
BMJ 2004 Oct 21;
http://www.bmj.com/content/329/7472/972.full
HSL992
Hensley S, Hollister H.
Pfizer Reports Solid Earnings;Wyeth Returns to Profitability Restrained Drug-Price Rise May Slow Growth
Wall Street Journal 2004 Oct 20
HSL993
Mitchell A.
PBS faces winds of change
Australian Financial Review 2004 Oct 20
HSL990
Pollack A.
A New Trial of Celebrex, and Questions on Its Timing
The New York Times 2004 Oct 19
HSL991
Hensley S.
FDA Says It Is Too Soon to Tell If Vioxx's Risks Apply to Class Merck's Recall Decision Raises Safety Questions In Similar Arthritis Drugs
Wall Street Journal 2004 Oct 19
HSL958
Gladwell M.
High Prices: How to think about prescription drugs.
The New Yorker 2004 Oct 18
HSL960
Masters B.
Painful Withdrawal for Makers of Vioxx: Pulling of Arthritis Drug Raises Questions on Marketing, Safety Risks
The Washington Post 2004 Oct 18
HSL988
Consumers Sue Pharmaceutical AstraZeneca Over Misleading Nexium Campaign - AFL-CIO joins suit alleging scheme to deceive consumers, increase profits
Prescription Access Litigation 2004 Oct 18
HSL989
Hensley S.
Pfizer to Test All-or-Nothing Bet Could Pave Way for Broader Use Of Popular Arthritis Drug
Wall Street Journal 2004 Oct 18
HSL17367
Tindall B
Better Playing Through Chemistry
The New York Times 2004 Oct 17
http://www.nytimes.com/2004/10/17/arts/music/17tind.html?pagewanted=all&position;=
HSL956
Abelson R.
Pfizer Warns of Risks From Its Painkiller
The New York Times 2004 Oct 16
HSL17366
Bowe C
Merck under spotlight for 'deal' with US drug regulators
The Finanical Times 2004 Oct 16
HSL20043
Kmietowicz Z
WMA sets rules on how doctors handle industry sponsorship
BMJ 2004 Oct 16;329:(876):
http://www.bmj.com//content/329/7471/876.1?variant=full-text
HSL954
Silverman E.
Drug maker promotes generics for workers Novartis draws fire on cost-cutting bid
The Star-Ledger 2004 Oct 15
HSL5473
Mansfield PR.
Reply to Stephen Black and Nicholas DeMartinis
2004 Oct 15;329:
http://bmj.bmjjournals.com/cgi/eletters/329/7468/748
HSL952
Herper M.
Merck's Missing Vioxx Study
Forbes 2004 Oct 14
HSL19513
Elliott S, Ives N
Questions on the $3.8 Billion Drug Ad Business
The New York Times 2004 Oct 12
http://www.nytimes.com/2004/10/12/business/media/12drug.html?ex=1098610045&ei=1&en=cbf357ef92d96a52
HSL19742
Kassirer J
Outlook: On the Take
The Washington Post 2004 Oct 12
http://www.washingtonpost.com/ac2/wp-dyn/A17496-2004Oct8?language=printer
HSL945
Goar C.
Is drug watchdog on duty for us?
Toronto Star 2004 Oct 11
HSL365
Mansfield PR.
Banned drug's world of faceless victims
The Independent Weekly (Adelaide) 2004 Oct 10-16
HSL5474
Mansfield PR, Tonkin AL, Jureidini JN.
Antidepressants do less good than harm for children and adolescents
BMJ 2004 Oct 8;329:
http://bmj.bmjjournals.com/cgi/eletters/329/7470/809
HSL19840
McLean B
Pharma breach penalties questioned
Australian Doctor 2004 Oct 8
http://www.australiandoctor.com.au/news/pharma-breach-penalties-questioned
HSL20052
Rayner F
Student ethics code stalled
Australian Doctor 2004 Oct 84
HSL20071
Hope A
Script patterns
Australian Doctor 2004 Oct 823
HSL940
Herper M.
Fuzzy Drug Company Math
Forbes 2004 Oct 5
HSL943
Haskell M.
New law cancels drug benefit Valium, Xanax among Rx cuts
Bangor Daily News 2004 Oct 5
HSL919
Boseley S.
Drugs licensing flaws exposed: Pfizer advised on how to get antidepressant approved by member of body deciding on application
The Guardian 2004 Oct 4
HSL921
Evans R.
The drugs industry and its watchdog: a relationship too close for comfort?
The Guardian 2004 Oct 4
HSL926
Brownlee S.
Mysteries of the Mind
The Washington Post 2004 Oct 4
HSL929
FDA should have required Vioxx safety study years ago, says Vanderbilt professor
SCRIP - World Pharmaceutical News 2004 Oct 4
HSL930
Regulators deal with aftermath of Vioxx withdrawal
SCRIP - World Pharmaceutical News 2004 Oct 4
HSL933
Pollack A.
New Scrutiny of Drugs in Vioxx's Family
New York Times 2004 Oct 4
HSL934
Wilde Mathews A
Vioxx Recall Raises Questions On FDA's Safety Monitoring
The Wall Street Journal 2004 Oct 4
HSL916
Freguson R.
MD deal aims to trim drugs for poor $50M fee hike if $200M in costs cut: Secret accord in tentative Ontario pact
The Toronto Star 2004 Oct 3
HSL880
Topol E.
Good Riddance to a Bad Drug
New York Times 2004 Oct 2
HSL881
Vioxx Withdrawal
ABC RN AM 2004 Oct 2
HSL3802
Benderly BL.
Advocacy groups are crucial players in developing new neurotherapeutics.
NeuroRx 2004 Oct 01;1:(4):500-2
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15717051
HSL879
Seaman B.
Treating infertility: Amid a confusing array of resources, how to decide which you can trust
Women's Review of Books 2004 Oct
HSL4759
Bensley RJ, Mercer N, Brusk JJ, Underhile R, Rivas J, Anderson J, Kelleher D, Lupella M, de Jager AC.
The eHealth Behavior Management Model: a stage-based approach to behavior change and management.
Prev Chronic Dis 2004 Oct;1:(4):A14
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15670446
HSL4896
Pecoul B.
New drugs for neglected diseases: from pipeline to patients.
PLoS Med 2004 Oct;1:(1):e6
HSL4937
Gupta AS.
Intellectual capital as property.
Indian J Med Ethics 2004 Oct-Dec;1:(4):115-6
HSL12935
Carver N, Ashmore R, Rolfe G, Cutcliffe J.
Anything to declare? Competing interests in mental health nursing journals.
Journal of Psychiatric & Mental Health Nursing 2004 Oct-Nov;11:(5):620-2
http://www.blackwellpublishing.com/journal.asp?ref=1351-0126&site=1
HSL15618
Weinstein J.
Why Advocacy Beats DTC
Pharmaceutical Executive 2004 Oct;
http://www.jweinsteinsm.com/img/PE%20Advoc%20article.pdf
HSL13272
Poor Markets, Rich Rewards: Pharmaceuticals and poor countries
The Economist 2004 Sep 3056
http://www.economist.com/business/displaystory.cfm?story_id=E1_PNVPDDQ
HSL5296
Abdolrasulnia M, Collins BC, Casebeer L, Wall T, Spettell C, Ray MN, Weissman NW, Allison JJ.
Using email reminders to engage physicians in an Internet-based CME intervention.
BMC Med Educ 2004 Sep 29;4:(17):
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=15453911
HSL878
Faunce T.
It's time - for a bipartisan stand-firm
Sydney Morning Herald 2004 Sep 28
HSL877
Schafer A.
Cracking down on medical trials
The Toronto Star 2004 Sep 27
HSL871
Kanapaux W.
FDA likely to add black box warning for antidepressants
First World 2004 Sep 24
HSL872
Shogren E.
Lawmakers Take FDA to Task on Antidepressants: A House subcommittee says the agency held back data on the drugs' risks to children
LA Times 2004 Sep 24
HSL873
Harris G.
Warnings Called Likely on Drug Risk for Suicide
The New York Times 2004 Sep 24
HSL874
Cohen R.
Regulators deny they covered up suicide info: FDA says antidepressant findings needed scrutiny
STAR-LEDGER 2004 Sep 24
HSL875
Vedantam S.
FDA Told Its Analyst to Censor Data on Antidepressants
The Washington Post 2004 Sep 24
HSL82
Raghavan A, Naik G
A Tie-Up of Aventis, Sanofi Could Create Strong Global Rival
The Wall Street Journal 2004 Sep 23
HSL870
Reuters .
US Reviewer Says Pressured in Antidepressant Probe
The New York Times 2004 Sep 23
HSL351
Cato J.
Pittman defense wants access to drug documents
The Herald 2004 Sep 22
HSL19740
Industry thought leaders critical to marketing success
eyeforpharma.com 2004 Sep 22
http://social.eyeforpharma.com/uncategorised/industry-thought-leaders-critical-marketing-success
Page 134 of 206 pages ‹ First < 132 133 134 135 136 > Last ›
